At the first ever Active Surveillance Convention, a conference I attended back in 2007, many experts openly bemoaned that the word “CANCER” profoundly overstates the significance of Gleason 6 type of prostate cancer. The pathologists at the conference, however, shot down the idea of a name change saying, “Under the microscope it looks like a cancer, so it is cancer.” No one at the conference had    a rebuttal so the proposal for a name change was dropped.

In this blog PCRI presents an interview from our contributing partner, Prostatepedia. 

Prostatepedia spoke with Dr. Charles G. Drake at length about current trends in immunotherapy for prostate cancer. Here is the interview:

In this blog PCRI presents an interview from our contributing partner, Prostatepedia. 

Mr. Jeff Lee, a mobile technology veteran, develops clinical trial apps for most major pharmaceutical companies. Prostatepedia spoke with him about how mobile technology streamlines the clinical trial experience for both patients and researchers alike. Here is the interview:

Yes, the PCRI Conference is a community or a village of people coming together to share the latest thoughts and ideas on how to deal with prostate cancer. And this, my friends, provides the ultimate calming effect; not only meeting others like you but also empowering each other with more knowledge and friendships and ultimately more solutions and peace of mind.

Donate with Charles "Snuffy" Myers today and help PCRI continue their lifesaving mission. 

PCRI's free Helpline connects patients and caregivers with educational advocates and helps them understand their personal case. This article is a top ten frequently asked questions list that our Helpline receives. 

Please Please (two “pleases” for emphasis) Consider Giving A Donation To PCRI This Year (AKA “Now please”) Because I Said So, And It Would Also Hurt My Feelings If You Did Not Donate Because I Am An Extremely Sensitive XY Chromosome (aka “man”). 

A new oral medication called ARAMIS is being evaluated in men who have rising PSA levels on Lupron and whose bone scans remain clear. For more information, visit: https://clinicaltrials.gov/show/NCT02200614

ARAMIS is similar to Xtandi but may have some advantages because ARAMIS is less likely to affect brain function which could reduce the likelihood of seizures and side effects...

GREETINGS RESEARCHER, and welcome to Prostate Insights! This publication is full of information concerning issues that surround prostate cancer. When dealing with a cancer diagnosis, the main focus is usually the cancer itself. While deciding what treatment to choose, patients may overlook critical issues; issues that most are not prepared to tackle.

This is a letter that we received from a recent helpline caller. It demonstrates the critical importance of support empowerment and information and how it prepares you for partnership with your medical professionals. This letter was published with permission from its author.